Longeveron: WHO Approves “Laromestrocel” for Lomecel-Bâ„¢ Stem Cell Therapy
Longeveron Inc. announced that the World Health Organization (WHO) has approved the International Non-proprietary Name (INN) “laromestrocel” for their cellular therapy Lomecel-Bâ„¢? Lomecel-Bâ„¢ is being evaluated as a treatment for Alzheimer?s disease and hypoplastic left heart syndrome (HLHS).? It is a proprietary product made from medicinal signaling cells and has received FDA designations such as […]
Pioneering Stem Cell Therapy Shows Promise in Alzheimer’s Treatment: Regeneration Biomedical Releases First Cohort Results
In a breakthrough for Alzheimer’s disease research, Regeneration Biomedical, Inc. recently presented promising findings from a Phase I clinical trial that delivers stem cell therapy directly into the brains of patients. Utilizing Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs), the therapy is designed to potentially slow or reverse the progression of Alzheimer’s. These specialized stem […]
Longeveron Unveils Promising Phase 2a Results for Regenerative Medicine and Cell Therapy in Mild Alzheimer’s Disease at AAIC 2024
Longeveron Inc., a leader in regenerative medicine and cell therapy, recently presented groundbreaking findings from their Phase 2a CLEAR MIND trial of Lomecel-B™ at the Alzheimer’s Association International Conference (AAIC) 2024. The trial focused on the efficacy and safety of Lomecel-B™, a medicinal signaling cell therapy, in treating mild Alzheimer’s Disease. Key Highlights: Implications for […]
Breakthrough in Alzheimer’s Treatment: Lomecel-B™ Receives RMAT Designation from FDA
Longeveron Inc., a clinical stage regenerative medicine biotechnology company, has achieved a significant milestone in the fight against Alzheimer’s Disease. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. This designation underscores the potential of Lomecel-B™ to provide a new […]
Regenerative Medicine: Induced Pluripotent Stem Cells (iPSCs) Therapy in Neurological Disorder Treatment
In recent years, the scientific community has been abuzz with the potential of induced pluripotent stem cells (iPSCs) for treating a myriad of diseases, especially neurological disorders. The allure of iPSCs lies in their ability to morph into any cell type in the human body, a characteristic termed as pluripotency. This remarkable trait is achieved […]
Unlocking the Brain’s Secret Weapon: The Power of Neural Stem Cells!
The Therapeutic Potential of Neural Stem Cells Imagine a construction site. The workers there are like cells in our body, each with a specific job to do. But among them, there are a few who are like the site managers, capable of taking on any role as needed. These are the stem cells, the body’s […]
Global Stem Cells Market to Generate Revenue of $25.68 Billion By 2028 | More than 80% of Revenue Comes from Adult Stem Cells
Westford,USA, Nov. 02, 2022 (GLOBE NEWSWIRE) — The demand for stem cells market is growing rapidly as the potential for their use in medical treatments expands. In particular, there is great interest in using stem cells to treat a range of degenerative diseases and injuries, as well as to improve the success of organ transplants. Recent advances […]
How Stem Cells Contribute to Aging and Age-Related Diseases with Rob Signer
What challenges does aging pose to both individuals and society at large? What causes aging at the cellular and molecular level? Stem cell research is the key to finding solutions that increase our healthspan and change how we think about aging. Robert A.J. Signer, Ph.D., shares what is on the horizon. Video Transcript: [MUSIC] What […]
Why Are Stem Cells The Future Of Medicine
Why do stem cells matter for the future of medicine? NYSCF’s Senior Vice President of Research Scott Noggle, PhD dives into the basics of stem cell research and what it means for diseases like Alzheimer’s, macular degeneration, and ALS. Watch Dr. Noggle’s full presentation here.
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]